Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries

dc.centroFacultad de Medicinaes_ES
dc.contributor.authorGarcía-Cortés, Miren
dc.contributor.authorOrtega-Alonso, Aida
dc.contributor.authorMatilla-Cabello, Gonzalo
dc.contributor.authorMedina-Cáliz, Inmaculada
dc.contributor.authorCastiella, Agustin
dc.contributor.authorConde, Isabel
dc.contributor.authorBonilla-Toyos, Elvira
dc.contributor.authorPinazo-Bandera, José M.
dc.contributor.authorHernandez, Nelia
dc.contributor.authorTagle, Martin
dc.contributor.authorNunes, Vinicius
dc.contributor.authorParana, Raymundo
dc.contributor.authorBessone, Fernando
dc.contributor.authorKaplowitz, Neil
dc.contributor.authorLucena-González, María Isabel
dc.contributor.authorÁlvarez-Álvarez, Ismael
dc.contributor.authorRobles-Díaz, María Mercedes
dc.contributor.authorAndrade-Bellido, Raúl Jesús
dc.date.accessioned2023-06-12T06:32:16Z
dc.date.available2023-06-12T06:32:16Z
dc.date.issued2023
dc.departamentoFarmacología y Pediatría
dc.description.abstractBackground & aims: Idiosyncratic drug-induced liver injury (DILI) with autoimmune features is a liver condition with laboratory and histological characteristics similar to those of idiopathic autoimmune hepatitis (AIH), which despite being increasingly re-ported, remains largely undefined. We aimed to describe in-depth the features of this entity in a large series of patients from two prospective DILI registries. Methods: DILI cases with autoimmune features collected in the Spanish DILI Registry and the Latin American DILI Network were compared with DILI patients without autoimmune features and with an independent cohort of patients with AIH. Results: Out of 1,426 patients with DILI, 33 cases with autoimmune features were identified. Female sex was more frequent in AIH patients than in the other groups (p= .001). DILI cases with autoimmune features had significantly longer time to onset (p< .001) and resolution time (p= .004) than those without autoimmune features. Interestingly, DILI patients with autoimmune features who relapsed exhibited significantly higher total bilirubin and transaminases at onset and absence of peripheral eosinophilia than those who did not relapse. The likelihood of relapse increased over time, from 17% at 6 months to 50% 4 years after biochemical normalization. Statins, nitrofurantoin and minocycline were the drugs most frequently associated with this phenotype. Conclusions: DILI with autoimmune features shows different clinical features than DILI patients lacking characteristics of autoimmunity. Higher transaminases and total bilirubin values with no eosinophilia at presentation increase the likelihood of relapse in DILI with autoimmune features. As the tendency to relapse increases over time, these patients will require long-term follow-up.es_ES
dc.description.sponsorshipInstituto de Salud Carlos III; Fondo Europeo de Desarrollo Regional— FEDER, Grant/Award Number: UMA18- FEDERJA-193, PI18/00901, PI19/00883 and PI21/01248; Consejería de Salud y Familia de la Junta de Andalucía, Grant/Award Number: P18-RT- 3364 and PI- 0310- 2018; Agencia Española del Medicamento; Sara Borrell, Grant/Award Number: CD20/00083; Rio Hortega, Grant/Award Number: CM21/00074; Garantía Juvenil, Grant/Award Number: SNGJ5Y6-09; Junta de Andalucía and European Social Fund; European Cooperation in Science and Technology; Universidad de Málaga/CBUA Funding for open access charge: Universidad de Málga / CBUAes_ES
dc.identifier.citationGarcía-Cortés M, Ortega-Alonso A, Matilla-Cabello G, et al. Clinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registries. Liver Int. 2023;00:1-12. doi:10.1111/liv.15623es_ES
dc.identifier.doihttps://doi.org/10.1111/liv.15623
dc.identifier.urihttps://hdl.handle.net/10630/26925
dc.language.isospaes_ES
dc.publisherWileyes_ES
dc.rightsAtribución-NoComercial 4.0 Internacional*
dc.rights.accessRightsopen accesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subjectHígado - enfermedadeses_ES
dc.subjectHepatitises_ES
dc.subject.otherAutoimmune featureses_ES
dc.subject.otherAutoimmune hepatitises_ES
dc.subject.otherDrug-induced autoimmune-like hepatitises_ES
dc.subject.otherDrug- induced liver injuryes_ES
dc.subject.otherHepatotoxicityes_ES
dc.titleClinical presentation, causative drugs and outcome of patients with autoimmune features in two prospective DILI registrieses_ES
dc.typejournal articlees_ES
dc.type.hasVersionVoRes_ES
dspace.entity.typePublication
relation.isAuthorOfPublicationcdb2c749-4a33-4bf5-8e83-4ee5c513f668
relation.isAuthorOfPublicationc049772e-c383-4e34-99ab-db30fe7ddfa3
relation.isAuthorOfPublication129ea2d9-e856-47ce-aa53-4f4af697017b
relation.isAuthorOfPublication4bb1f619-da0e-40a4-a809-0687a455f6be
relation.isAuthorOfPublicationa6176e8b-aafd-4214-af5c-8343612c72ca
relation.isAuthorOfPublication.latestForDiscoverycdb2c749-4a33-4bf5-8e83-4ee5c513f668

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Liver International - 2023 - Garc a‐Cort s - Clinical presentation causative drugs and outcome of patients with autoimmune.pdf
Size:
836.3 KB
Format:
Adobe Portable Document Format
Description:

Collections